Alexander Arkhipov
Overview
Explore the profile of Alexander Arkhipov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arkhipov A, Shao Z, Muirhead S, Harry M, Batool M, Mirzaee H, et al.
Plants (Basel)
. 2024 Nov;
13(21).
PMID: 39519980
The use of plant growth-promoting rhizobacteria presents a promising addition to conventional mineral fertilizer use and an alternative strategy for sustainable agricultural crop production. However, genotypic variations in the plant...
2.
Arkhipov A, Trofimovich K, Arkhipov N, Gabdullin P
Nanomaterials (Basel)
. 2024 Oct;
14(20).
PMID: 39453020
The possible contribution of phonon drag effect to the thermoelectrically sustained potential of a heated nanoisland on a semiconductor surface was estimated in a first principal consideration. We regarded electrons...
3.
Tewari K, Colombo N, Monk B, Dubot C, Caceres M, Hasegawa K, et al.
JAMA Oncol
. 2023 Dec;
10(2):185-192.
PMID: 38095881
Importance: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent,...
4.
Monk B, Colombo N, Tewari K, Dubot C, Caceres M, Hasegawa K, et al.
J Clin Oncol
. 2023 Nov;
41(36):5505-5511.
PMID: 37910822
JCO The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed...
5.
Monk B, Tewari K, Dubot C, Caceres M, Hasegawa K, Shapira-Frommer R, et al.
Lancet Oncol
. 2023 Mar;
24(4):392-402.
PMID: 36878237
Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus...
6.
Himaya S, Arkhipov A, Yum W, Lewis R
Mar Drugs
. 2022 Mar;
20(3).
PMID: 35323508
Cone snail venom biodiversity reflects dietary preference and predatory and defensive envenomation strategies across the ≈900 species of . To better understand the mechanisms of adaptive radiations in closely related...
7.
Syed-Ab-Rahman S, Arkhipov A, Wass T, Xiao Y, Carvalhais L, Schenk P
J Appl Microbiol
. 2022 Jan;
132(4):3111-3124.
PMID: 35061923
Aim: To understand how beneficial bacteria assist chilli plants (Capsicum annuum) in defence against biotrophic or hemibiotrophic pathogens. Method And Results: We quantified marker genes of plant defence pathways in...
8.
Bizyaev I, Gabdullin P, Chumak M, Babyuk V, Davydov S, Osipov V, et al.
Nanomaterials (Basel)
. 2021 Dec;
11(12).
PMID: 34947699
Herein, we describe a study of the phenomenon of field-induced electron emission from thin films deposited on flat Si substrates. Films of Mo with an effective thickness of 6-10 nm...
9.
Colombo N, Dubot C, Lorusso D, Caceres M, Hasegawa K, Shapira-Frommer R, et al.
N Engl J Med
. 2021 Sep;
385(20):1856-1867.
PMID: 34534429
Background: Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)-positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy...